Pipeline

Program tRNA Synthetase Target/MOA Indication Preclinical Phase 1 Phase 2 Phase 3
Efzofitimod HARS NRP2 modulator Pulmonary Sarcoidosis(1)
 
SSc-ILD
 
Other ILD
(CTD-ILD; CHP)
 
ATYR0101 DARS LTBP1 modulator Fibrosis
 
ATYR0750 AARS FGFR4 modulator Liver Disorders
 
tRNA Synthetase Candidates(2)
 
Program/
Target
Indication Phase
Efzofitimod
NRP2 modulator
Pulmonary Sarcoidosis(1) Phase 3
SSc-ILD Phase 2
Other ILD (CTD-ILD; CHP) Phase 1
ATYR0101
LTBP1 modulator
Fibrosis Preclinical
ATYR0750
FGFR4 modulator
Liver Disorders Preclinical
tRNA Synthetase Candidates(2) Preclinical

(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
(2) Pipeline candidates in development based on additional tRNA synthetases from IP portfolio
ODD = orphan drug designation; SSc-ILD = Scleroderma-related ILD; CTD-ILD = Connective Tissue Disease-ILD; CHP = Chronic Hypersensitivity Pneumonitis

© 2007 - 2024   aTyr Pharma.   Legal   Privacy Policy